Abstracts tagged "ANCA"

Abstract Number: 2903 • 2014 ACR/ARHP Annual Meeting
Early Outcomes in Pediatric Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV)
Kimberly Morishita¹, Susanne Benseler², Rae S.M. Yeung³, Thomas Mason II⁴, Dawn Wahezi⁵, Kenneth N. Schikler⁶, Erica F. Lawson⁷, Susan Nielsen⁸, Sirirat Charuvanij⁹, Paul Dancey¹⁰, Susan Shenoi¹¹, Linda Wagner-Weiner¹², Angelyne Sarmiento¹, David A. Cabral¹³ and For the PedVas Initiative¹, ¹BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada, ³Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology - Department of Medicine, Mayo Clinic, Rochester, MN, ⁵Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁶Department of Pediatrics, Univ of Louisville Schl of Med, Louisville, KY, ⁷Pediatrics, University of California, San Francisco, San Francisco, CA, ⁸Pediatric rheumatology, Rigshospitalet, Copenhagen, Denmark, ⁹Pediatrics, Siriraj Hospital, Bangkok, Thailand, ¹⁰Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, ¹¹Pediatric Rheumatology, Seattle Childrens Hospital, seattle, WA, ¹²Pediatric Rheumatology, University of Chicago Hospital, Chicago, IL, ¹³Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Childhood AAV is rare and outcome studies are limited. The PedVas Study is an international initiative collecting clinical data (to A Registry of Childhood…
Abstract Number: 85 • 2014 ACR/ARHP Annual Meeting
Protective Association of HLA-DRB1*13:02 Against MPO-ANCA Positive ANCA-Associated Vasculitis in a Japanese Population
Naoyuki Tsuchiya¹, Narumi Hasebe¹, Ken-ei Sada², Shigeto Kobayashi³, Hidehiro Yamada⁴, Hiroshi Furukawa⁵, Kunihiro Yamagata⁶, Takayuki Sumida⁷, Nobuyuki Miyasaka⁸, Seiichi Matsuo⁹, Shigeto Tohma⁵, Shoichi Ozaki¹⁰, Hiroshi Hashimoto¹¹, Hirofumi Makino², Masayoshi Harigai¹² and Aya Kawasaki¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, ⁴Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ⁶Department of Internal Medicine (Nephrology), Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁷Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁸Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁹Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹⁰Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ¹¹Juntendo University School of Medicine, Tokyo, Japan, ¹²Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose Epidemiology of antineutrophil cytoplasmic antibody (ANCA) – associated vasculitis (AAV) is substantially different between European and Asian populations. In the Japanese population, the majority…
Abstract Number: 2278 • 2014 ACR/ARHP Annual Meeting
Orbital Pseudotumor As the Presenting Symptom of Pediatric ANCA-Associated Vasculitis
Amanda Schlefman¹, Maureen Leffler², AnneMarie C. Brescia³ and Carlos D. Rose⁴, ¹A.I. DuPont Hospital for Children, Wilmington, DE, ²Rheumatology, AI duPont Hospital for Children, Wilmington, DE, ³Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ⁴Pediatrics, Division of Rheumatology, Nemours A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE
Background/Purpose: Ocular involvement, particularly orbital pseudotumor, has been reported as the initial manifestation of ANCA-associated vasculitis (AAV) in the adult population, predominantly in granulomatosis with…
Abstract Number: 2186 • 2014 ACR/ARHP Annual Meeting
Clinical and Immunologic Correlates in Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies
Christian Lood and Grant C. Hughes, Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Illicit cocaine use is associated with the development of serum anti-neutrophil cytoplasmic autoantibodies (ANCA) and a variety of clinical manifestations. However, the mechanisms linking…
Abstract Number: 1863 • 2014 ACR/ARHP Annual Meeting
CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Pirow Bekker¹, David Jayne², Annette Bruchfeld³, Matthias Schaier⁴, Kazimierz Ciechanowski⁵, Lorraine Harper⁶, Michel Jadoul⁷, Mårten Segelmark⁸, Daina Selga⁹, Istvan Szombati¹⁰, Michael Venning¹¹, Christian Hugo¹², Paul L. van Daele¹³, Ondrej Viklicky¹⁴, Antonia Potarca¹⁵ and Thomas J. Schall¹⁵, ¹Medical & Clinical Affairs, Chemocentryx, Inc., Mountain View, CA, ²Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ³Karolinska Institute, Stockholm, Sweden, ⁴University of Heidelberg, Heidelberg, Germany, ⁵Pomeranian Medical University, Szczecin, Poland, ⁶Nephrology, University of Birmingham, Birmingham, United Kingdom, ⁷Cliniques Saint-Luc, Brussels, Belgium, ⁸Nephrology, Linkobing University, Linkoping University, Linkoping, Sweden, ⁹Lund University, Lund, Sweden, ¹⁰Budaclinic, Budapest, Hungary, ¹¹Manchester University, Manchester, United Kingdom, ¹²Dresden University, Dresden, Germany, ¹³Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ¹⁴Instit of Clin and Exp Med, Prague, Czech Republic, ¹⁵ChemoCentryx, Inc., Mountain View, CA
Background/Purpose: CCX168 is a potent, specific C5aR inhibitor in clinical development for ANCA-associated vasculitis. The initial focus of this randomized, double-blind, placebo-controlled clinical trial was…
Abstract Number: 1862 • 2014 ACR/ARHP Annual Meeting
The Association of Low-Density Granulocytes with Disease Activity and Response to Treatment in ANCA-Associated Vasculitis
Peter C. Grayson¹, Carmelo Carmona-Rivera¹, Lijing Xu², Noha Lim², Adam Asare², Deborah J. Phippard², Mariana J. Kaplan³, Peter A. Merkel⁴ and Paul A. Monach⁵, ¹NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ²Immune Tolerance Network, Bethesda, MD, ³Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA
Background/Purpose: To discover new pathways involved in the pathophysiology of ANCA-associated vasculitis (AAV) and identify potential clinical biomarkers through use of whole-genome gene expression profiling.…
Abstract Number: 754 • 2013 ACR/ARHP Annual Meeting
Outcome Of Kidney Transplantation In Paediatric Patients With ANCA Associated Glomerulonephritis: A Single-Center Experience
Marinka Twilt¹, Damien Noone², Wesley Hayes², Paul Thorner³, Susanne M. Benseler⁴, Ronald M. Laxer⁴, Rulan Parekh² and Diane Hebert², ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Nephrology, The Hospital for Sick Children, Toronto, ON, Canada, ³Pathology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Kidney transplant outcomes for paediatric patients with end stage kidney disease (ESKD) secondary to ANCA GN, particularly granulomatosis with polyangiitis (GPA) and microscopic polyangiitis…
Abstract Number: 755 • 2013 ACR/ARHP Annual Meeting
Survival Of Patients With ANCA-Associated Vasculitides In Chronic Dialysis In France From 2002 To 2011: Data From The National Rein Registry
Manon Romeu¹, Cécile Couchoud Sr.², Jean-Christophe Delarozière³, Laurent Chiche Sr.⁴, Jean-Robert Harle⁵, Bertrand Gondoin⁶, Stéphane Burtey⁶, Philippe Brunet⁶, Yvon Berland⁶ and Noémie Jourde-Chiche Sr.⁷, ¹Nephrology, Aix-Marseille Universite, APHM, Marseille, France, ²registre REIN, agence de la biomédecine, paris, France, ³public health, APHM, Marseille, France, ⁴Internal Medicine, CHU Marseille, Marseille, France, ⁵Internal Medicine, APHM, Marseille, France, ⁶Nephrology, APHM, Marseille, France, ⁷Nephrology, Aix-Marseille Université - APHM, Marseille, France
Background/Purpose: Despite dramatic outcome improvement in ANCA-associated vasculitides (AAV), renal involvement is still leading to end-stage renal disease (ESRD) in 20-30% of patients. This study…
Abstract Number: 760 • 2013 ACR/ARHP Annual Meeting
Cluster Analysis To Explore Clinical Subclassification Of Eosinophilic Granulomatosis With Polyangiitis (Churg–Strauss)
Thomas Neumann¹, Frank Moosig², Augusto Vaglio³, Jochen Zwerina⁴, Renato Alberto Sinico⁵, Wojciech Szczeklik⁶, Paolo Bottero⁷, Phillip Bremer⁸, Andrea Gioffredi⁹, Barbara Sokolowska⁶, Luca Di Toma⁵, Federica Maritati⁹, Julian Großkreutz¹⁰, Claus Kroegel¹¹, Matthieu Resche-Rigon¹² and Alfred Mahr¹³, ¹Jena University Hospital, Internal Medicine III, Jena, Germany, ²Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ³Unit of Nephrology, University Hospital of Parma, Parma, Italy, ⁴Ludwig Bolzmann institut of osteology at the 4th medical departmen, Hanusch Hospital, Vienna, Austria, ⁵Clinical Immunology Unit and Renal Unit, Department of Medicine, Azienda Ospedaliera Ospedale San Carlo Borromeo, Milan, Italy, ⁶Department of Medicine, Jagiellonian University Medical College, Krakow, Poland, ⁷llergy and Clinical Immunology Unit, Magenta Hospital, Magenta, Italy, ⁸University Hospital Schleswig Holstein and Klinikum Bad Bramstedt, Bad Bramstedt, Germany, ⁹Department of Clinical Medicine, Nephrology and Health Sciences, University of Parma, Parma, Italy, ¹⁰Department of Neurology, Jena University-Hospital, Jena, Germany, ¹¹Jena University Hospital, Internal Medicine I, Jena, Germany, ¹²Biostatistics, Hopital Saint-Louis, Paris, France, ¹³Department of Internal Medicine, Hospital Saint-Louis, Paris, France
Background/Purpose: Results from descriptive studies of eosinophilic granulomatosis with polyangiitis (EGPA) suggest distinct clinical subclasses that may be determined by anti-neutrophil cytoplasmic antibody (ANCA) status.…
Abstract Number: 729 • 2013 ACR/ARHP Annual Meeting
Role Of Innate Immunity In The Pathogenesis Of ANCA-Associated Vasculitis
Angelica Gattamelata¹, Giovanna Peruzzi², Rossana Scrivo³, Roberta Priori³, Stefania Morrone⁴, Angela Santoni² and Guido Valesini³, ¹Sapienza University of Rome, Rome, Italy, ²Department of Molecular Medicine, Sapienza University, Rome, Italy, ³Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁴Department of Experimental Medicine, Sapienza University, Rome, Italy
Background/Purpose: Natural killer cells (NK) represent one of the main effectors of the innate immune response through the defense against viral infections and the production…
Abstract Number: 733 • 2013 ACR/ARHP Annual Meeting
Plasma Levels Of Fibrin/Fibrinogen Degradation Products Might Be a Useful Indicator Of Disease Activity, Classification and Nephritis Complications In Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Kuninobu Wakabayashi, Nao Oguro, Yoko Miura, Sho Ishii, Shinya Seki, Masayu Umemura, Takahiro Tokunaga, Hiroyuki Tsukamoto, Sakiko Isojima, Hidekazu Furuya, Ryo Yanai, Kumiko Otsuka, Ryo Takahashi, Takeo Isozaki, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: It is important to determine the biomarkers for assessing disease activity of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Plasma levels of fibrin/fibrinogen…
Abstract Number: 734 • 2013 ACR/ARHP Annual Meeting
The Significance Of Anti-Myeloperoxidase and Anti-Proteinase 3 Antibodies In The Absence Of Anti-Neutrophil Cytoplasmic Antibody Immunofluorescence Positivity
Deepak A. Rao¹, Joseph F. Merola¹, William R. O'Brien¹, Kevin Wei¹, Samuel U. Takvorian², Paul F. Dellaripa³ and Peter H. Schur¹, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Identification of serum anti-neutrophil cytoplasmic antibodies (ANCA) for the detection of ANCA-associated vasculitis (AAV) is often performed by screening with indirect immunofluorescence (IF), followed…
Abstract Number: 736 • 2013 ACR/ARHP Annual Meeting
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Associated With Systemic Sclerosis In Japan: A Review Of The Literature
Natsumi Nagao¹, Yuri Sadanaga¹, Satoko Tashiro¹, Rie Suematsu¹, Syuichi Koarada¹, Akihide Ohta² and Yoshifumi Tada¹, ¹Rheumatology, Saga University, Saga, Japan, ²Nursing, Saga University, Saga, Japan
Background/Purpose: Cases of Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) during the course of systemic sclerosis (SSc) have recently been reported. Japanese cases of AAV associated…
Abstract Number: 149 • 2013 ACR/ARHP Annual Meeting
Comparative Proteomic Analysis Of Neutrophils From Patients With Microscopic Polyangiitis and Granulomatosis With Polyangiitis
Teisuke Uchida¹, Kohei Nagai², Toshiyuki Sato³, Nobuko Iizuka³, Mitsumi Arito³, Yukiko Takakuwa⁴, Hiromasa Nakano⁴, Seido Ooka⁴, Manae Kurokawa³, Naoya Suematsu³, Kazuki Okamoto³, Shoichi Ozaki⁵ and Tomohiro Kato³, ¹Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, kawasaki, Japan, ²Department of Genetic Engineering, Faculty of Biology-Oriented Science and Technology, Kinki University, Wakayama, Japan, ³Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, ⁴Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Both microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) belong to ANCA-associated vasculitis (AAV), in which neutrophils are thought to be involved in their…
Abstract Number: 738 • 2013 ACR/ARHP Annual Meeting
Pulmonary Fibrosis In ANCA-Associated Vasculitis
Cloé Comarmond¹, Bruno Crestani², Abdellatif Tazi³, Baptiste Hervier⁴, Sylvain Adam-Marchand⁵, Hilario Nunes⁶, Fleur Cohen-Aubart⁷, Marie Wislez⁸, Jacques Cadranel⁸, Bruno Housset⁹, Célia Lloret-Linares¹⁰, Pascal Sève¹¹, Christian Pagnoux¹², Sébastien Abad¹³, Juliette Camuset¹⁴, Boris Bienvenu¹⁵, Michael Duruisseaux¹⁶, Eric Hachulla¹⁷, Jean-Benoît Arlet¹⁸, Mohamed Hamidou¹⁹, Alfred Mahr²⁰, Anne-Laure Brun²¹, Philippe Grenier²¹, Patrice Cacoub²² and David Saadoun²³, ¹Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, ²Pneumology A, Hôpital Bichat, Paris, France, ³Hôpital Saint-Louis, Paris, France, ⁴Internal Medicine & Clinical Immunology Dpt, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁵Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, ⁶Department of Pneumology, Avicenne Hospital (AP-HP), Bobigny, France, ⁷Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁸Pneumology, Hôpital Tenon, Paris, France, ⁹Pneumology, Centre Hospitalier Intercommunal de Créteil, Créteil, France, ¹⁰Médecine Interne A, Hôpital Lariboisière, Paris, France, ¹¹Internal medicine, CHU Lyon, Lyon, France, ¹²Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ¹³Internal Medicine, Avicenne Hospital, Bobigny, France, ¹⁴Pneumology, Centre Hospitalier Victor Dupouy, Argenteuil, France, ¹⁵Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ¹⁶Pneumology, CHU de Grenoble, Grenoble, France, ¹⁷Internal Medicine, Lille CEDEX, France, ¹⁸Internal Medicine, HEGP, Paris, France, ¹⁹Internal Medicine Department, Nantes University Hospital, Nantes, France, ²⁰Department of Internal Medicine, Hospital Saint-Louis, Paris, France, ²¹Radiology, Hôpital Pitié-Salpêtrière, Paris, France, ²²Médecine Interne 2, Hopital Pitié-Salpétrière, Paris, France, ²³Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France
Background/Purpose: The association of pulmonary fibrosis (PF) with anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), especially microscopic polyangiitis (MPA), is rare but related to poor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.